[{"AccountsPayableCurrent_0_Q3_USD":568000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_3_Q3_USD":422000.0,"MarketableSecuritiesCurrent_0_Q3_USD":181443000.0,"ProceedsFromSaleOfProductiveAssets_3_Q3_USD":29000.0,"OtherLiabilitiesNoncurrent_0_Q3_USD":11050000.0,"ProceedsFromIssuanceOfDebt_3_Q3_USD":2962000.0,"IncreaseDecreaseInAccountsAndOtherReceivables_3_Q3_USD":-177000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":2658000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":1250000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q3_USD":45190000.0,"OtherLiabilitiesCurrent_0_Q3_USD":2362000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_3_Q3_USD":55600000.0,"AccountsAndOtherReceivablesNetCurrent_0_Q3_USD":838000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3_Q3_USD":7.99,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q3_USD":9.25,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":-11000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":14000.0,"GainLossOnSaleOfPropertyPlantEquipment_3_Q3_USD":29000.0,"OtherLiabilities_0_Q3_USD":13412000.0,"StockIssuedDuringPeriodValueOther_1_Q3_USD":4297000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_3_Q3_USD":-37880000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q3_USD":-14224000.0,"DepreciationDepletionAndAmortization_3_Q3_USD":3174000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-37891000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-14210000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":1278523000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":1250000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":181431000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":23000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":11000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_3_Q3_pure":0.006,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3_Q3_pure":0.91,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_3_Q3_pure":0.98,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":3633000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":668000.0,"RepaymentsOfDebt_3_Q3_USD":2962000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3_Q3_USD":0.0,"ProceedsFromStockPlans_3_Q3_USD":218000.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":183394000.0,"OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_0_Q3_USD":0.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":3801000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":2545000.0,"OtherAssetsNoncurrent_0_Q3_USD":41000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":1263000.0,"IndefiniteLivedIntangibleAssetsExcludingGoodwill_0_Q3_USD":45200000.0,"IncreaseDecreaseInEquitySecuritiesFvNi_3_Q3_USD":0.0,"ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3_Q3_USD":3500000.0,"ContractWithCustomerLiabilityRevenueRecognized_3_Q3_USD":200000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q3_USD":0.0,"ContractWithCustomerLiability_0_Q3_USD":553000.0,"ContractWithCustomerAssetNet_0_Q3_USD":0.0,"ConstructionInProgressExpendituresIncurredButNotYetPaid_3_Q3_USD":63000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":6919000.0,"BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0_Q3_USD":107500000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_3_Q3_USD":4236000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_1_Q3_USD":-662000.0,"InvestmentsAndCash_0_Q3_USD":199600000.0,"IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3_Q3_USD":-37880000.0,"IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1_Q3_USD":-14224000.0,"DeferredTaxLiabilities_0_Q3_USD":2779000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":2493000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":1305000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-35193000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-129070000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":171182000.0,"LiabilitiesCurrent_0_Q3_USD":12200000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":255770000.0,"Liabilities_0_Q3_USD":25795000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":1280000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":-228000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-38108000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-14224000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":170964000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":10833000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-1.44,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.36,"CostsAndExpenses_3_Q3_USD":42206000.0,"CostsAndExpenses_1_Q3_USD":15010000.0,"CommonStockValue_0_Q3_USD":40000.0,"CommonStockSharesOutstanding_0_Q3_shares":39562472.0,"CommonStockSharesIssued_0_Q3_shares":39562472.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":18151000.0,"AssetsCurrent_0_Q3_USD":202925000.0,"Assets_0_Q3_USD":255770000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":3074832.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":2608000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":3640000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3_Q3_pure":0.005,"PropertyPlantAndEquipmentNet_0_Q3_USD":3813000.0,"StockholdersEquity_0_Q3_USD":229975000.0,"BusinessCombinationContingentConsiderationLiability_0_Q3_USD":8249000.0,"InterestReceivable_0_Q3_USD":300000.0,"InterestAndOtherIncome_3_Q3_USD":465000.0,"InterestAndOtherIncome_1_Q3_USD":118000.0,"IncreaseDecreaseInOtherOperatingLiabilities_3_Q3_USD":-1491000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3_Q3_USD":864000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1_Q3_pure":0.005,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1_Q3_pure":0.98,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3_Q3_pure":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1_Q3_pure":0.0,"ShareBasedCompensation_3_Q3_USD":2658000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":32109000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-1051196000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":10708000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"PreferredStockSharesAuthorized_0_Q3_shares":3000000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.01,"OperatingIncomeLoss_3_Q3_USD":-38573000.0,"OperatingIncomeLoss_1_Q3_USD":-14342000.0,"CommonStockSharesAuthorized_0_Q3_shares":297000000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"CommitmentsAndContingencies_0_Q3_USD":null,"AccruedLiabilitiesCurrent_0_Q3_USD":8007000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":26303000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":39278000.0,"PreferredStockValue_0_Q3_USD":null,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q3_USD":194000.0,"Ticker":"CLDX","CIK":"744218","name":"CELLDEX THERAPEUTICS, INC.","OfficialName":"Celldex Therapeutics Inc.","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1601609341.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20201105"}]